Exelixis, Inc. (EXEL)
54.45
-0.81
(-1.47%)
USD |
NASDAQ |
Aug 28, 16:00
54.42
-0.03
(-0.06%)
After-Hours: 20:00
Exelixis Free Cash Flow : 1.172B for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.172B |
| March 31, 2026 | 917.69M |
| December 31, 2025 | 875.84M |
| September 30, 2025 | 779.77M |
| June 30, 2025 | 754.07M |
| March 31, 2025 | 820.89M |
| December 31, 2024 | 671.54M |
| September 30, 2024 | 432.69M |
| June 30, 2024 | 277.54M |
| March 31, 2024 | 279.60M |
| December 31, 2023 | 292.86M |
| September 30, 2023 | 367.40M |
| June 30, 2023 | 361.43M |
| March 31, 2023 | 265.18M |
| December 31, 2022 | 334.91M |
| September 30, 2022 | 343.42M |
| June 30, 2022 | 310.20M |
| March 31, 2022 | 452.70M |
| December 31, 2021 | 336.58M |
| September 30, 2021 | 275.09M |
| June 30, 2021 | 218.09M |
| March 31, 2021 | 151.51M |
| December 31, 2020 | 178.64M |
| September 30, 2020 | 310.40M |
| June 30, 2020 | 372.14M |
| Date | Value |
|---|---|
| March 31, 2020 | 407.95M |
| December 31, 2019 | 514.12M |
| September 30, 2019 | 465.06M |
| June 30, 2019 | 540.83M |
| March 31, 2019 | 472.85M |
| December 31, 2018 | 382.42M |
| September 30, 2018 | 316.38M |
| June 30, 2018 | 203.78M |
| March 31, 2018 | 145.28M |
| December 31, 2017 | 144.47M |
| September 30, 2017 | 191.94M |
| June 30, 2017 | 146.68M |
| March 31, 2017 | 116.52M |
| December 31, 2016 | 204.59M |
| September 30, 2016 | 85.70M |
| June 30, 2016 | 59.97M |
| March 31, 2016 | 59.21M |
| December 31, 2015 | -142.03M |
| September 30, 2015 | -156.26M |
| June 30, 2015 | -180.12M |
| March 31, 2015 | -208.53M |
| December 31, 2014 | -235.88M |
| September 30, 2014 | -233.30M |
| June 30, 2014 | -232.86M |
| March 31, 2014 | -218.27M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| BioMarin Pharmaceutical, Inc. | 725.08M |
| Cytokinetics, Inc. | -580.72M |
| Emergent BioSolutions, Inc. | 85.90M |
| Gilead Sciences, Inc. | 12.94B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 307.74M |
| Cash from Investing (Quarterly) | 91.43M |
| Cash from Financing (Quarterly) | -343.88M |
| Free Cash Flow Per Share (Quarterly) | 1.159 |
| Free Cash Flow to Equity (Quarterly) | 304.54M |
| Free Cash Flow to Firm (Quarterly) | 300.92M |
| Free Cash Flow Yield | 7.96% |